

NEWS RELEASE

MDxHealth Announces Agreement with HIFU CLINIC Prostate Cancer Center for Distribution of SelectMDx in Poland

Further broadens reach of SelectMDx™ for Prostate Cancer in Europe

IRVINE, CA, and HERSTAL, BELGIUM – October 19, 2016 – MDxHealth SA (Euronext: MDXH.BR) a multinational healthcare company that provides actionable epigenetic information to personalize the diagnosis and treatment of urologic cancers, today announced an agreement with the HIFU CLINIC Prostate Cancer Center (HIFU CLINIC) for distribution of its SelectMDx™ for Prostate Cancer liquid biopsy assay throughout Poland. HIFU CLINIC will be the second distributor of SelectMDx in Poland.

Marek Filipek, MD, PhD, HIFU CLINIC Medical Director, stated: “Bringing the SelectMDx assay to the Polish market is a turning point in providing an advanced prostate cancer diagnostic decision tool that is both sensitive and specific to Polish Patients and their Physicians. The well-validated, non-invasive SelectMDx liquid biopsy test stands out in a growing field of yet unproven tools. Early identification of patients at risk for clinically significant prostate cancer is the key to accurate patient selection for prostate biopsy, with likely benefit to long term clinical outcomes.”

“We are very pleased to announce our collaboration with HIFU CLINIC, whose High Intensity Focused Ultrasound (HIFU) Clinic is the first and only Polish center dedicated entirely to the comprehensive diagnostics and modern treatment of prostate cancer. SelectMDx will perfectly complement HIFU CLINIC’s cutting edge diagnostic methods and procedures,” **commented Dr. Jan Groen, CEO of MDxHealth.** “We believe this key partnership will help us improve awareness and widen access to SelectMDx throughout Poland.”

About SelectMDx for Prostate Cancer

Of the nearly 2 million prostate biopsies performed each year, less than a third find cancer. Most of these men could have avoided a painful and invasive prostate biopsy procedure, with its associated complications and costs. SelectMDx for Prostate Cancer is a proprietary urine-based, molecular diagnostic test that offers a non-invasive 'liquid biopsy' method to assess a man's risk for prostate cancer. SelectMDx helps identify men at increased risk of harbouring aggressive, potentially lethal, prostate cancer who may benefit most from a prostate biopsy and earlier detection. The test delivers a negative predictive value (NPV) of 98% for clinically significant disease, helping to reduce unnecessary MRI procedures and invasive prostate biopsies by approximately 50%, thereby reducing healthcare costs.

About HIFU CLINIC Prostate Cancer Center

HIFU CLINIC Prostate Cancer Center is a unique private initiative dedicated to bringing innovative medical care solutions in diagnostics and therapy to the global patient base in cooperation with VEDI CLINIC Men's Health Clinic and AMEDS Medical Center. The Group is an experienced regional leader in the global medical tourism market in regard to, but not limited to, Men's Health. HIFU CLINIC Prostate Cancer Center and VEDI CLINIC Men's Health Clinic serve as providers of advanced diagnostic and treatment options to prostate

cancer and erectile dysfunction patients. For more information visit: www.hifuclinic.eu or follow us on Twitter <https://twitter.com/hifuclinic>.

About MDxHealth

MDxHealth is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The company's tests are based on proprietary gene methylation (epigenetic) and other molecular technologies and assist physicians with the diagnosis of cancer, prognosis of recurrence risk, and prediction of response to a specific therapy. For more information, visit mdxhealth.com and follow us on Twitter at: twitter.com/mdxhealth.

For more information:

Dr. Jan Groen, CEO
MDxHealth

US: +1 949 812 6979

BE: +32 4 364 20 70

info@mdxhealth.com

Jonathan Birt, Chris Welsh, Hendrik Thys, Cameron Standage
(PR & IR)

Consilium Strategic Communications

UK: +44 20 3709 5701

US: +1 917 322 2571 (Rx Communications Group LLC)

mdxhealth@consilium-comms.com

This press release contains forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the company's control, and may turn out to be materially different. MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of MDxHealth in any jurisdiction. No securities of MDxHealth may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. securities laws.

NOTE: The MDxHealth logo, MDxHealth, ConfirmMDx, SelectMDx, AssureMDx and PredictMDx are trademarks or registered trademarks of MDxHealth SA. All other trademarks and service marks are the property of their respective owners.